C4 Therapeutics Reports 53% Response Rate for Cemsidomide at RP2D

MT Newswires Live06-11

C4 Therapeutics (CCCC) said Phase 1 data to be presented at the European Hematology Association 2026 Congress showed its investigational drug cemsidomide achieved a 53% overall response rate at the recommended Phase 2 dose in heavily pretreated patients with relapsed or refractory multiple myeloma, the company said Thursday.

The study included 73 heavily pretreated patients with a median of seven prior therapies, with 75% previously treated with BCMA-directed therapy and 75% previously treated with CAR-T or T-cell engager therapies, showing a 36% overall response rate across all doses, with deeper responses at higher dose levels, the company said.

C4 Therapeutics said cemsidomide showed a manageable safety profile, with no discontinuations deemed related to cemsidomide and minimal dose reductions related to safety or tolerability, and noted complete responses and MRD negativity at the 100 microgram dose level.

The data support continued development of cemsidomide in relapsed or refractory multiple myeloma, with further studies across lines of therapy and in combination with approved therapies planned, it added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2642281863?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-11 19:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642281863","market":"us","top_or_hot":-1,"title":"C4 Therapeutics Reports 53% Response Rate for Cemsidomide at RP2D","media":"MT Newswires Live","content":"<html><body><p> C4 <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CCCC) said Phase 1 data to be presented at the European Hematology Association 2026 Congress showed its investigational drug cemsidomide achieved a 53% overall response rate at the recommended Phase 2 dose in heavily pretreated patients with relapsed or refractory multiple myeloma, the company said Thursday.</p><p>The study included 73 heavily pretreated patients with a median of seven prior therapies, with 75% previously treated with BCMA-directed therapy and 75% previously treated with CAR-T or T-cell engager therapies, showing a 36% overall response rate across all doses, with deeper responses at higher dose levels, the company said.</p><p>C4 Therapeutics said cemsidomide showed a manageable safety profile, with no discontinuations deemed related to cemsidomide and minimal dose reductions related to safety or tolerability, and noted complete responses and MRD negativity at the 100 microgram dose level.</p><p>The data support continued development of cemsidomide in relapsed or refractory multiple myeloma, with further studies across lines of therapy and in combination with approved therapies planned, it added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>C4 Therapeutics Reports 53% Response Rate for Cemsidomide at RP2D</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nC4 Therapeutics Reports 53% Response Rate for Cemsidomide at RP2D\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-11 19:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> C4 <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CCCC) said Phase 1 data to be presented at the European Hematology Association 2026 Congress showed its investigational drug cemsidomide achieved a 53% overall response rate at the recommended Phase 2 dose in heavily pretreated patients with relapsed or refractory multiple myeloma, the company said Thursday.</p><p>The study included 73 heavily pretreated patients with a median of seven prior therapies, with 75% previously treated with BCMA-directed therapy and 75% previously treated with CAR-T or T-cell engager therapies, showing a 36% overall response rate across all doses, with deeper responses at higher dose levels, the company said.</p><p>C4 Therapeutics said cemsidomide showed a manageable safety profile, with no discontinuations deemed related to cemsidomide and minimal dose reductions related to safety or tolerability, and noted complete responses and MRD negativity at the 100 microgram dose level.</p><p>The data support continued development of cemsidomide in relapsed or refractory multiple myeloma, with further studies across lines of therapy and in combination with approved therapies planned, it added.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CCCC","symbol_name":"C4 Therapeutics, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2642281863","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642281863","pubTimestamp":1781178406,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"C4 Therapeutics  said Phase 1 data to be presented at the European Hematology Association 2026 Congress showed its investigational drug cemsidomide achieved a 53% overall response rate at the recommended Phase 2 dose in heavily pretreated patients with relapsed or refractory multiple myeloma, the company said Thursday.The study included 73 heavily pretreated patients with a median of seven prior therapies, with 75% previously treated with BCMA-directed therapy and 75% previously treated with CAR-T or T-cell engager therapies, showing a 36% overall response rate across all doses, with deeper responses at higher dose levels, the company said.C4 Therapeutics said cemsidomide showed a manageable safety profile, with no discontinuations deemed related to cemsidomide and minimal dose reductions related to safety or tolerability, and noted complete responses and MRD negativity at the 100 microgram dose level.The data support continued development of cemsidomide in relapsed or refractory multi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CCCC":"C4 Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"C4 Therapeutics报告Cemsidomide在RP2D时的缓解率为53%","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CCCC":1.5},"content_text":"C4 Therapeutics (CCCC) said Phase 1 data to be presented at the European Hematology Association 2026 Congress showed its investigational drug cemsidomide achieved a 53% overall response rate at the recommended Phase 2 dose in heavily pretreated patients with relapsed or refractory multiple myeloma, the company said Thursday.The study included 73 heavily pretreated patients with a median of seven prior therapies, with 75% previously treated with BCMA-directed therapy and 75% previously treated with CAR-T or T-cell engager therapies, showing a 36% overall response rate across all doses, with deeper responses at higher dose levels, the company said.C4 Therapeutics said cemsidomide showed a manageable safety profile, with no discontinuations deemed related to cemsidomide and minimal dose reductions related to safety or tolerability, and noted complete responses and MRD negativity at the 100 microgram dose level.The data support continued development of cemsidomide in relapsed or refractory multiple myeloma, with further studies across lines of therapy and in combination with approved therapies planned, it added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2642281863","isCrawlerRequest":true}